Published on : Jun 21, 2016
ALBANY, New York, June 21, 2016: ResearchMoz.us has added a report, titled “Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016,” to its expanding database. The research report analyzes the pharmaceutical, biotechnology, diagnostic, and other life science sectors from a ground-up manner with a special focus on business moves in the recent years in these sectors. It provides a detailed analysis of mergers and acquisitions (M&As) and terms and agreements announced in the aforementioned industry sectors elaborating upon their impact on the respective industry’s progression. Insights into the market drivers, restraints, trends, and opportunities are also provided for the aforementioned business sectors for the 2010-2016 period.
The report presents a detailed analysis of reasons why companies enter into M&As, partnerships, and other alliances for business growth in biotechnology, life sciences, pharmaceutical, and diagnostic sectors. In particular, M&A is a constant activity in the biopharma sector. Biopharma companies are consistently striving for mergers and acquisitions with competitor companies with the aim to attain an advantage in both R&D and sales and marketing areas. This ensures continued growth and dominance in a highly competitive marketplace.
The pharma sector has witnessed some significant business alliances in the last three decades, says the report. In 1987, the top ten companies were responsible for almost 12% of global pharmaceutical sales. By 2002, the sales of these companies accounted for 50% of global sales on account of some of the mega business alliances in this sector. The inclusion of M&A case studies in the pharma sector between 2010 and 2016 is a notable feature of this report.
Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=729070
In the last couple of years, some notable trends have come to the fore in the pharma sector. Big pharma companies have recognized the high returns of successful marketing and sales of blockbuster drugs thus striving to maximize the same. Whilst licensing has been the traditional means for companies to achieve a global presence, big pharma companies are increasingly seeking business alliances to enter into large pharmaceutical markets. Pharma companies are deviating from mega-merger practices to smaller acquisitions to strengthen R&D pipelines.
The research report is a vital instrument for its valuable offerings about business alliances in the biopharma sector. It contains online links to M&A deal records that have been executed since 2010, including online copies of merger and acquisition contract papers as submitted to the Securities Exchange Commission wherever these were available. Contract documents provide answers to numerous questions that prospective partners would be interested in. They present a fair idea about the flexibility of a company that a prospective partner company can leverage to derive value from a future deal.
The research report is presented in a chapter-wise format for reading comprehensibility. Each chapter is further divided into sub-chapters, which discuss various aspects of merger and acquisition partnership structure at length. The report contains an array of graphical representations to depict the M&A deal structure pictorially.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]